US Patent

US9724360 — Methods for treating Filoviridae virus infections

Composition of Matter · Assigned to Gilead Sciences Inc · Expires 2035-10-29 · 9y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections, including Marburg, Ebola, and Cueva viruses.

USPTO Abstract

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

Drugs covered by this patent

Patent Metadata

Patent number
US9724360
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-10-29
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.